API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
Details:
Vecoxan joins Elanco’s previously announced Osurnia® and Capstar® divestitures, and divestiture of European Economic Area and U.K.
Lead Product(s): Diclazuril,Methyl 4-Hydroxybenzoate,Propyl 4-Hydroxybenzoate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $55.0 million Upfront Cash: $55.0 million
Deal Type: Agreement February 19, 2020